Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians.
BACKGROUND
The degree of ADHD-related difficulties - reflecting overall impairment, social functioning, and quality of life - may be perceived differently by adolescent patients, parents and physicians. The primary aim of this study was to investigate ADHD-related difficulties during atomoxetine treatment, as perceived by the three different raters. Secondary objectives focused on effectiveness and tolerability of atomoxetine treatment in a population of adolescent patients with ADHD.


METHODS
Adolescents with ADHD, aged 12-17 years, received open-label atomoxetine (0.5-1.2 mg/kg/day) up to 24 weeks. ADHD-related difficulties at various times of the day were rated using the Global Impression of Perceived Difficulties (GIPD) instrument. Inter-rater agreement was analyzed using Cohen's Kappa with 95% confidence intervals (95% CI). ADHD-Rating Scale (ADHD-RS) and Clinical Global Impression Severity (GGI-S) scores were assessed by the investigator; and spontaneous adverse events, vital signs and laboratory parameters were collected for tolerability assessments.


RESULTS
159 patients received atomoxetine. Patients' baseline mean GIPD total ratings were significantly lower than parents' and physicians' scores (12.5 [95%CI 11.6;13.5] vs. 17.2 [16.2;18.2] and 18.8 [17.8;19.8]). For all raters, GIPD scores significantly improved over time. Changes were greatest within the first two weeks. Kappa coefficients varied between 0.186 [0.112;0.259] and 0.662 [0.529;0.795], with strongest agreements between parent and physician assessments, and significant improvements of patient/physician agreements over time (based on 95% CIs). ADHD-RS and CGI-S scores significantly improved over the course of the study (based on 95% CIs). Tolerability results were consistent with earlier reports.


CONCLUSIONS
ADHD-related difficulties were perceived differently by the raters in this open-label trial, but consistently improved during atomoxetine treatment. The GIPD instrument appeared sensitive to treatment-related change. These primarily quantitative findings may guide future studies to more systematically investigate the clinical and practical relevance of the differences observed. Additionally, in order to further validate these results, placebo- and comparator-controlled trials are recommended as well as inclusion of healthy controls and other patient populations.


BACKGROUND



BACKGROUND
ClinicalTrials.gov: NCT00191737.
Dittmann
Ralf W
RW
Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg, Germany. ralf.dittmann@zi-mannheim.de
Wehmeier
Peter M
PM
Schacht
Alexander
A
Minarzyk
Anette
A
Lehmann
Martin
M
Sevecke
Kathrin
K
Lehmkuhl
Gerd
G
Child Care Health Dev. 2006 Jul;32(4):397-406
16784495
Curr Med Res Opin. 2007 Feb;23(2):379-94
17288692
Pediatrics. 2004 Jul;114(1):e1-8
15231966
Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):10
18507847
Eur Child Adolesc Psychiatry. 2004 Aug;13(4):249-57
15365896
J Dev Behav Pediatr. 2004 Aug;25(4):264-71
15308927
J Pediatr. 2006 Jul;149(1):112-9
16860138
J Clin Psychol. 2001 Apr;57(4):571-85
11255207
J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):966-75
10434488
J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2):149-157
16429085
Clin Ther. 2006 Nov;28(11):1892-908
17213010
Expert Rev Pharmacoecon Outcomes Res. 2006 Aug;6(4):379-90
20528508
J Am Acad Child Adolesc Psychiatry. 2002 May;41(5):530-7
12014785
Pediatrics. 2001 Nov;108(5):E83
11694667
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I102-16
15322961
Pediatrics. 2005 Sep;116(3):e364-9
16140679
Qual Life Res. 2000;9(8):887-900
11284208
Pediatrics. 2004 Nov;114(5):e541-7
15520087
J Dev Behav Pediatr. 2004 Jun;25(3):166-74
15194901
J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):240-8
15725968
Psychopharmacol Bull. 1985;21(4):714-1124
3911249
J Clin Psychiatry. 2002;63 Suppl 12:10-5
12562056
Eur Child Adolesc Psychiatry. 2006 Dec;15 Suppl 1:I38-45
17177014
J Child Adolesc Psychopharmacol. 2007 Dec;17(6):813-30
18315453
J Child Adolesc Psychopharmacol. 2009 Jun;19(3):253-63
19519260
Clin Pediatr (Phila). 2006 Nov;45(9):819-27
17041169
Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11
18507848
Med Care. 2004 Mar;42(3):210-20
15076820
Lancet. 2005 Jul 16-22;366(9481):237-48
16023516
Psychopharmacology (Berl). 2007 Oct;194(2):197-209
17572882
J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):137-46
11214601
J Child Adolesc Psychopharmacol. 2006 Dec;16(6):713-24
17201615
Am J Psychiatry. 2002 Nov;159(11):1896-901
12411225
Pediatrics. 2002 Dec;110(6):e75
12456942
J Clin Psychiatry. 2002 Dec;63(12):1140-7
12523874
Value Health. 1999 Mar-Apr;2(2):113-27
16674343